Immunic, Inc.
IMUX
$1.17
-$0.03-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.26M | 5.98M | 5.71M | 5.29M | 4.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.33M | 25.99M | 27.08M | 26.83M | 25.63M |
| Operating Income | -23.33M | -25.99M | -27.08M | -26.83M | -25.63M |
| Income Before Tax | -19.30M | -25.58M | -26.82M | -25.47M | -25.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.30M | -25.58M | -26.82M | -25.47M | -25.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.30M | -25.58M | -26.82M | -25.47M | -25.18M |
| EBIT | -23.33M | -25.99M | -27.08M | -26.83M | -25.63M |
| EBITDA | -23.29M | -25.95M | -27.04M | -26.78M | -25.60M |
| EPS Basic | -0.10 | -0.13 | -0.27 | -0.28 | -0.25 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.17 | -0.16 | -0.16 |
| EPS Diluted | -0.10 | -0.13 | -0.27 | -0.28 | -0.25 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.17 | -0.16 | -0.16 |
| Average Basic Shares Outstanding | 194.32M | 193.90M | 98.65M | 90.15M | 100.70M |
| Average Diluted Shares Outstanding | 194.32M | 193.90M | 98.65M | 90.15M | 100.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |